NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $90.88
  • Forecasted Upside: 9.93 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$82.67
▼ -1.51 (-1.79%)

This chart shows the closing price for ENTA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Enanta Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ENTA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ENTA

Analyst Price Target is $90.88
▲ +9.93% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Enanta Pharmaceuticals in the last 3 months. The average price target is $90.88, with a high forecast of $130.00 and a low forecast of $55.00. The average price target represents a 9.93% upside from the last price of $82.67.

This chart shows the closing price for ENTA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 contributing investment analysts is to buy stock in Enanta Pharmaceuticals. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/11/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/9/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
12/8/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
3/8/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
6/6/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
9/4/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
11/3/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/3/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/24/2021OppenheimerBoost Price TargetMarket Perform$55.00 ➝ $73.00High
11/23/2021Roth CapitalLower Price TargetBuy$107.00 ➝ $101.00High
11/23/2021SVB LeerinkLower Price TargetMarket Perform$92.00 ➝ $85.00High
11/23/2021JMP SecuritiesBoost Price TargetOutperform$111.00 ➝ $116.00High
11/19/2021Royal Bank of CanadaLower Price TargetSector Perform$74.00 ➝ $72.00High
11/19/2021JMP SecuritiesLower Price TargetMarket Outperform$121.00 ➝ $111.00High
11/8/2021SVB LeerinkBoost Price TargetMarket Perform$55.00 ➝ $92.00High
11/8/2021JMP SecuritiesBoost Price TargetMarket Outperform$77.00 ➝ $121.00High
11/8/2021Robert W. BairdBoost Price TargetOutperform$71.00 ➝ $130.00High
10/20/2021JMP SecuritiesReiterated RatingBuy$73.00 ➝ $78.00Medium
10/20/2021Royal Bank of CanadaBoost Price TargetSector Perform$58.00 ➝ $74.00Medium
10/6/2021Jefferies Financial GroupInitiated CoverageBuy$95.00High
9/9/2021SVB LeerinkInitiated CoverageMarket Perform$55.00High
8/6/2021Royal Bank of CanadaLower Price TargetSector Perform$52.00 ➝ $50.00High
8/6/2021JMP SecuritiesBoost Price TargetOutperform$70.00 ➝ $77.00High
2/9/2021Royal Bank of CanadaBoost Price TargetIn-Line ➝ Sector Perform$47.00 ➝ $53.00Low
1/29/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$44.00 ➝ $55.00High
11/24/2020Royal Bank of CanadaLower Price TargetSector Perform$52.00 ➝ $45.00High
11/23/2020Evercore ISIInitiated CoverageUnderperform$30.00High
10/26/2020Roth CapitalBoost Price TargetBuy$104.00 ➝ $107.00Low
9/23/2020OppenheimerReiterated RatingHold$55.00Low
8/27/2020Roth CapitalReiterated RatingBuy$104.00High
8/25/2020Piper SandlerInitiated CoverageOverweight$87.00High
8/6/2020Royal Bank of CanadaReiterated RatingHoldLow
8/4/2020OppenheimerInitiated CoverageHold$55.00High
7/27/2020JMP SecuritiesUpgradeMarket Perform ➝ Outperform$70.00High
5/7/2020OppenheimerReiterated RatingHold$62.00Medium
4/8/2020Royal Bank of CanadaReiterated RatingHold$49.00High
3/17/2020Robert W. BairdUpgradeNeutral ➝ Outperform$60.00High
11/22/2019JMP SecuritiesDowngradeOutperform ➝ Market PerformHigh
9/26/2019JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$86.00 ➝ $57.00High
9/18/2019Berenberg BankSet Price TargetBuy$130.00Low
5/24/2019Wolfe ResearchInitiated CoverageOutperform ➝ Outperform$117.00Medium
4/23/2019Berenberg BankUpgradeHold ➝ Buy$80.00 ➝ $120.00High
12/13/2018Berenberg BankInitiated CoverageHold ➝ Hold$80.00High
11/27/2018OppenheimerSet Price TargetHold$100.00High
8/14/2018OppenheimerSet Price TargetHold$100.00Medium
8/8/2018UBS GroupDowngradeOutperform ➝ Market PerformHigh
7/31/2018JMP SecuritiesReiterated RatingBuy$120.00Low
6/7/2018OppenheimerInitiated CoverageBuy$135.00High
6/6/2018Roth CapitalInitiated CoverageBuy$133.00High
5/24/2018OppenheimerInitiated CoverageBuy$135.00Medium
4/4/2018Royal Bank of CanadaReiterated RatingHold$80.00Low
2/8/2018Royal Bank of CanadaBoost Price TargetSector Perform$78.00High
2/8/2018JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralHigh
1/2/2018Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$54.00Medium
11/21/2017Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$54.00 ➝ $58.00N/A
10/20/2017Royal Bank of CanadaReiterated RatingBuy$54.00N/A
10/4/2017JMP SecuritiesBoost Price Target$40.00 ➝ $53.00Low
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ OutperformHigh
8/9/2017JPMorgan Chase & Co.Reiterated RatingOverweight$32.00 ➝ $38.00Low
8/8/2017Robert W. BairdBoost Price TargetNeutral$27.00 ➝ $36.00Medium
7/11/2017JMP SecuritiesUpgradeMarket Perform ➝ Outperform$40.00High
(Data available from 12/4/2016 forward)

News Sentiment Rating

0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/8/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/7/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/7/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/6/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/5/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/5/2021
  • 2 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
11/4/2021
  • 8 very positive mentions
  • 22 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
12/4/2021

Current Sentiment

  • 8 very positive mentions
  • 22 positive mentions
  • 4 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Enanta Pharmaceuticals logo
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
Read More

Today's Range

Now: $82.67
Low: $81.68
High: $85.59

50 Day Range

MA: $77.45
Low: $54.10
High: $97.37

52 Week Range

Now: $82.67
Low: $40.32
High: $102.00

Volume

144,001 shs

Average Volume

250,456 shs

Market Capitalization

$1.68 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Enanta Pharmaceuticals?

The following Wall Street research analysts have issued stock ratings on Enanta Pharmaceuticals in the last twelve months: Jefferies Financial Group Inc., JMP Securities, JPMorgan Chase & Co., Oppenheimer Holdings Inc., Robert W. Baird, Roth Capital, Royal Bank of Canada, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for ENTA.

What is the current price target for Enanta Pharmaceuticals?

8 Wall Street analysts have set twelve-month price targets for Enanta Pharmaceuticals in the last year. Their average twelve-month price target is $90.88, suggesting a possible upside of 9.9%. Robert W. Baird has the highest price target set, predicting ENTA will reach $130.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $55.00 for Enanta Pharmaceuticals in the next year.
View the latest price targets for ENTA.

What is the current consensus analyst rating for Enanta Pharmaceuticals?

Enanta Pharmaceuticals currently has 4 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ENTA will outperform the market and that investors should add to their positions of Enanta Pharmaceuticals.
View the latest ratings for ENTA.

What other companies compete with Enanta Pharmaceuticals?

How do I contact Enanta Pharmaceuticals' investor relations team?

Enanta Pharmaceuticals' physical mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company's listed phone number is (617) 607-0800 and its investor relations email address is [email protected] The official website for Enanta Pharmaceuticals is www.enanta.com.